Resistin-like molecule beta (RELMβ) is a gut-derived cytokine involved in both allergic responses and protection from pathogens, and it has been previously found to be dysregulated in mouse models of food allergy (FA). Researchers from Boston Children’s Hospital aimed assess the potential of RELMβ as a novel biomarker in children with FA.
It has been demonstrated that stem cell factor (SCF) and its receptor KIT play key roles in the differentiation, proliferation, survival, migration and activation of mast cells, which in turn play a central role in the development of IgE-mediated allergic diseases, including allergic urticaria and food allergy.
It is known that Bruton tyrosine kinase (BTK) is an essential enzyme for the FcεRI signaling pathway and is thought to be a target to prevent IgE-mediated allergic reactions. Researchers have hypothesized that the BTK inhibitor acalabrutinib may prevent reactivity to peanuts in patients with peanut allergy.
Researchers from Revolo Biotherapeutics Ltd. have presented preclinical data for IRL-201104, a clinical-stage immunomodulatory peptide that has previously demonstrated a long-lasting effect in different preclinical models of allergic inflammation. In the new studies, the candidate was assessed in models of food allergy.
Environmental factors, such as those from food allergens, can modulate IgE-driven hypersensitivity related to the genetics of allergy. Researchers from the Korea National Institute of Health aimed to investigate the impact of polymorphisms in the SORBS1 gene in relation to atopic dermatitis based on milk exposure.
At the ongoing AAAAI meeting in San Antonio, researchers from Escient Pharmaceuticals Inc. presented preclinical data for the Mas-related G-protein coupled receptor X2 (MRGPRX2) antagonist EP-262, being evaluated as a novel therapeutic approach for mast cell-mediated diseases. In vitro, EP-262 acted as a potent and highly selective antagonist of MRGPRX2, which inhibited MRGPRX2 activation induced by a wide variety of agonists.
Nektar Therapeutics Inc. President and CEO Howard Robin didn’t mince words during a call with investors after market close Feb. 23 to disclose top-line data from a phase II study testing rezpegaldesleukin (rezpeg) in systemic lupus erythematosus, which fell short of partner Eli Lilly and Co.’s criteria for advancing to phase III and raised uncertainty as to how the big pharma might proceed in other indications such as atopic dermatitis (AD).
Researchers from PDS Biotechnology Corp. and affiliated organizations have detailed the development and preclinical evaluation of recombinant protein vaccines formulated with enantio-specific cationic lipid R-DOTAP.